Associated Papers
Polymorphisms in androgen metabolism genes AR, CYP1B1, CYP19, and SRD5A2and prostate cancer risk and aggressiveness in Bulgarian patients.
Kachakova D et al.
Turkish Journal of Medical Sciences, 2016
Phenotype, genotype and gender identity in a large cohort of patients from India with 5α-reductase 2 deficiency.
Shabir I et al.
Andrology, 2015
Association of V89L SRD5A2 polymorphism with craving and serum leptin levels in male alcohol addicts.
Lenz B et al.
Psychopharmacology, 2012
Genetic impact on prostate anatomical variability during ageing: role of CYP17, SRD5A2 and androgen receptor genes polymorphisms.
Larré S et al.
Bju International, 2007
Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.
Cunningham JM et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2007
The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
Giwercman YL et al.
European Urology, 2005
Functional genetic polymorphisms and female reproductive disorders: Part I: Polycystic ovary syndrome and ovarian response.
Simoni M et al.
Human Reproduction Update, 0
Select a paper to view details